文献速递血栓与止血

血浆补体C5浓度升高与未来静脉血栓栓塞风险相关

Elevated plasma concentration of complement factor C5 is associated with risk of future venous thromboembolism.
PubMed 文献 · Blood · 2021-01-01

在Tromsø研究的巢式病例对照研究中(415例VTE患者与848名年龄性别匹配对照),血浆C5水平与未来VTE风险呈阈值效应,最高三分位组年龄性别调整OR为1.45(95%CI 1.07-1.96),无诱因VTE的OR为1.70(95%CI 1.11-2.60)。C5水平不受基因组或C5相关基因变异调控,仅轻微受慢性炎症影响。

要点

  • 血浆C5最高三分位组与未来VTE风险增加相关,无诱因VTE关联更强。
  • C5水平与VTE风险呈阈值效应,高于最低三分位即风险增加。
  • C5水平不受基因变异调控,慢性炎症影响轻微。

核心结论

  • 血浆C5浓度升高与未来静脉血栓栓塞风险增加相关,且无诱因VTE关联更显著。

研究设计与样本

  • 基于Tromsø研究的巢式病例对照研究,纳入415例VTE患者和848名年龄性别匹配对照,检测入组时血浆C5水平。

主要发现

  • 最高三分位组C5水平与最低三分位组相比,年龄性别调整VTE风险OR为1.45(95%CI 1.07-1.96)。
  • 无诱因VTE的OR为1.70(95%CI 1.11-2.60)。
  • 调整BMI和CRP对风险估计影响较小。
  • 采血至VTE事件时间越短,OR增加越明显。
  • 全外显子组测序和蛋白数量性状位点分析未发现基因组或C5相关基因变异与C5水平相关。

临床怎么用

  • 血浆C5水平可能作为未来VTE风险的参考指标,尤其对于无诱因VTE。
  • C5水平不受基因变异调控,检测时无需考虑遗传背景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The role of complement in the pathogenesis of venous thromboembolism (VTE) is unclear. We wanted to investigate (1) whether plasma complement component C5 (C5) levels are influenced by genetic variants or chronic inflammation and (2) the association between plasma C5 and risk of future VTE in a nested case-control study of 415 patients with VTE and 848 age- and sex-matched controls derived from the Tromsø Study. Plasma C5 levels were measured at inclusion. Odds ratios (ORs) with 95% confidence intervals (95% CIs) for provoked and unprovoked VTE across tertiles of C5 concentrations were estimated by logistic regression. Adjustment for C-reactive protein (CRP) served as a proxy for general inflammation. Whole-exome sequencing and protein quantitative trait loci analyses were performed to assess genetic influence on C5 concentrations. There was no association between genome-wide or C5-related gene variants and C5 levels. The association between plasma C5 levels and VTE risk displayed a threshold effect, where subjects with C5 levels above the lowest tertile had increased risk of VTE. Subjects in tertile 3 (highest C5 levels) had an age- and sex-adjusted OR of 1.45 (95% CI, 1.07-1.96) compared with tertile 1 (lowest). These statistics were more pronounced for unprovoked VTE (OR, 1.70; 95% CI, 1.11-2.60). Adjustments for body mass index and CRP had minor impact on risk estimates. The OR increased substantially with shorter time between blood sampling and VTE event. In conclusion, plasma C5 was associated with risk of future VTE. C5 levels were not genetically regulated and were only slightly influenced by chronic inflammation.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Skjeflo EW, Brækkan SK, Ludviksen JK, et al. Elevated plasma concentration of complement factor C5 is associated with risk of future venous thromboembolism. Blood. 2021. PMID: 34339498. doi:10.1182/blood.2021010822

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。